摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(+/-)-6-fluoro-3,4-dihydro-4-oxo-2H-1-benzopyran-2-carbonyl chloride | 118803-66-0

中文名称
——
中文别名
——
英文名称
(+/-)-6-fluoro-3,4-dihydro-4-oxo-2H-1-benzopyran-2-carbonyl chloride
英文别名
6-fluoro-3,4-dihydro-4-oxo-2H-1-benzopyran-2-carbonyl chloride;6-Fluoro-4-oxo-2,3-dihydrochromene-2-carbonyl chloride
(+/-)-6-fluoro-3,4-dihydro-4-oxo-2H-1-benzopyran-2-carbonyl chloride化学式
CAS
118803-66-0
化学式
C10H6ClFO3
mdl
——
分子量
228.607
InChiKey
BITVFKNLNHZOGI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.2
  • 重原子数:
    15
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.2
  • 拓扑面积:
    43.4
  • 氢给体数:
    0
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Hydantoin derivatives for treating complications of diabetes
    申请人:Sanwa Kagaku Kenkyusho Co., Ltd.
    公开号:US04861792A1
    公开(公告)日:1989-08-29
    Hydantoin derivatives and salts thereof, intermediates therefor, process for the preparation thereof, and medicines containing the derivative, wherein said derivatives have the formula ##STR1## wherein one of V and W is hydrogen and the other is a halogenomethyl group, 1H-tetrazol-5-yl radical, --COOR group, in which R is hydrogen atom, an alkyl group, --(CH.sub.2 CH.sub.2 O)nCH.sub.3 group (n is an integer of 1 to 113) or substituted phenyl, ##STR2## in which R.sub.1 and R.sub.2 are same or different independently, each is hydrogen atom, an alkyl group, substituted phenyl or --(CH.sub.2 CH.sub.2 O)nCH.sub.3 group (n has the meaning as referred to) or R.sub.1 may form a heterocyclic ring together with R.sub.2 and nitrogen or oxygen atom, ##STR3## in which R.sub.2 and R.sub.4 are same or different independently and each is hydrogen atom or an alkyl group, X is oxygen or sulfur atom, and Y and Z are same or different independently and each is hydrogen atom, a halogen atom, alkyl group, alkoxy group, alkylmercapto group, nitro radical or --NHR.sub.5 group, in which R.sub.5 is hydrogen atom or an acyl group. The derivatives and salts thereof are useful for the treatment of complications of diabetes.
    Hydantoin衍生物及其盐,其中间体,其制备方法,以及含有该衍生物的药物,其中所述衍生物具有以下公式##STR1##其中V和W中的一个是氢,另一个是卤代甲基基团,1H-四唑-5-基团,-COOR基团,其中R是氢原子,烷基基团,-(CH.sub.2 CH.sub.2 O)nCH.sub.3基团(n为1至113的整数)或取代苯基,##STR2##其中R.sub.1和R.sub.2分别相同或不同,每个都是氢原子,烷基基团,取代苯基或-(CH.sub.2 CH.sub.2 O)nCH.sub.3基团(n的含义如上所述)或R.sub.1可以与R.sub.2和氮或氧原子一起形成杂环,##STR3##其中R.sub.2和R.sub.4分别相同或不同,每个都是氢原子或烷基基团,X是氧或硫原子,Y和Z分别相同或不同,每个是氢原子,卤原子,烷基基团,烷氧基团,烷基硫基团,硝基基团或-NHR.sub.5基团,其中R.sub.5是氢原子或酰基。这些衍生物及其盐对于治疗糖尿病并发症是有用的。
  • Process for preparing optically active hydantoins
    申请人:Sanwa Kagaku Kenkyyusho Co., Ltd.
    公开号:US05001240A1
    公开(公告)日:1991-03-19
    Hydantoin derivatives and salts thereof, intermediates therefor, process for the preparation thereof, and medicines containing the derivatives, wherein said derivatives have the formula ##STR1## wherein one of V and W is hydrogen and the other is a halogenomethyl group, 1H-tetrazol-5-yl radical, --COOR group, in which R is hydrogen atom, an alkyl group, --(CH.sub.2 CH.sub.2 O)nCH.sub.3 group (n is an integer of 1 to 113) or substituted phenyl, ##STR2## group, in which R.sub.1 and R.sub.2 are same or different independently, each is hydrogen atom, an alkyl group, substituted phenyl or --(CH.sub.2 CH.sub.2 O)nCH.sub.3 group (n has the meaning as referred to) or R.sub.1 may form a heterocyclic ring together with R.sub.2 and nitrogen or oxygen atom, --CH.sub.2 OR.sub.3 group or ##STR3## group, in which R.sub.3 and R.sub.4 are same or different independently and each is hydrogen atom or an alkyl group, X is oxygen or sulfur atom, and Y and Z are same or different independently and each is hydrogen atom, a halogen atom, alkyl group, alkoxy group, alkylmercapto group, nitro radical or --NHR.sub.5 group, in which R.sub.5 is hydrogen atom or an acyl group. The derivatives and salts thereof are useful for the treatment of complications of diabetes.
    Hydantoin衍生物及其盐,其中间体,其制备方法,以及含有该衍生物的药物,其中所述的衍生物具有以下结构式##STR1##其中V和W中的一个是氢,另一个是卤代甲基基团,1H-四唑-5-基团,-COOR基团,其中R是氢原子,烷基基团,-(CH.sub.2 CH.sub.2 O)nCH.sub.3基团(n为1至113的整数)或取代的苯基,##STR2##基团,其中R.sub.1和R.sub.2分别相同或不同,每个是氢原子,烷基基团,取代的苯基或-(CH.sub.2 CH.sub.2 O)nCH.sub.3基团(n的含义如上所述)或R.sub.1可以与R.sub.2和氮或氧原子一起形成杂环,-CH.sub.2 OR.sub.3基团或##STR3##基团,其中R.sub.3和R.sub.4分别相同或不同,每个是氢原子或烷基基团,X是氧或硫原子,Y和Z分别独立相同或不同,每个是氢原子,卤素原子,烷基基团,烷氧基团,烷基硫基团,硝基基团或-NHR.sub.5基团,其中R.sub.5是氢原子或酰基。该衍生物及其盐对于糖尿病并发症的治疗是有用的。
  • US4861792A
    申请人:——
    公开号:US4861792A
    公开(公告)日:1989-08-29
  • US4978758A
    申请人:——
    公开号:US4978758A
    公开(公告)日:1990-12-18
  • US4985573A
    申请人:——
    公开号:US4985573A
    公开(公告)日:1991-01-15
查看更多